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Ketamine, an N-methyl-D-aspartic acid receptor complex antagonist, has been used as an anesthetic and/
or analgesic. However, in the past decade, ketamine has been illegally available as a recreational drug in
Asian countries and Taiwan. Due to the characteristic of being short-acting, youngsters widely assume
that ketamine is not as harmful as other drugs, such as heroin. Consequently, many young patients used
this drug for a longer duration before they presented with severe urinary frequency and urgency
symptoms. Subsequently, other cases have been reported in Taiwan, Hong Kong, Singapore, Malaysia,
and Europe. Ketamine abuse is increasing, with rates of 0.30% in 2006 to 0.40% in 2007 among those in
the 16e59 year age group. In general, affected patients tend to be young with a peak age range of 16e35
years. The incidence of lower urinary tract symptoms in ketamine abuse patients is around 30%. The
actual underlying pathomechanism of ketamine cystitis (KC) and associated pelvic pain remains unclear.
It is speculated that chronic contact and stimulation to the bladder or ureteral mucosa due to metabolites
of ketamine will result in submucosal edema, vascular ectasia, ﬁbrosis, detrusor muscle inﬂammation,
and ﬁbrosis. Presentations of KC include remarkable dysuria, urinary frequency/urgency, urge inconti-
nence, and bladder pain. Urine culture usually fails to yield any microbiology in KC with bladder pain
alone. The majority of patients can enjoy clinical improvement after cessation of ketamine and urological
treatment similar to interstitial cystitis/bladder pain syndrome (IC/BPS). However, patients who are still
abusing ketamine and/or who have a longer duration of ketamine abuse might suffer from severe
bladder pain, which does not respond to empirical oral or intravesical treatments such as hyaluronic acid.
Among these patients, most have a remarkably impaired quality of life and are at risk of developing
upper urinary tract damage, including hydronephrosis and kidney injury. To reduce bladder pain,
improve quality of life, and avoid further deterioration of renal function, surgical intervention might be
indicated.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ketamine, an N-methyl-D-aspartic acid receptor complex
antagonist, has been used as an anesthetic or analgesic since the
1960s.1 It remains the most commonly used anesthetic in veteri-
nary medicine, is an anesthetic agent in children, and is used in
chronic pain. The psychosis-like symptoms induced by ketamine
have been used as a pharmacological model of schizophrenia.2
These effects have also led to the recreational use of ketamine.ddhist Tzu Chi General Hos-
ien, Taiwan.
ociation. Published by Elsevier TaDue to its easy availability and low risk of crime, it has become
increasingly used for recreational purposes in Hong Kong,
Singapore, Malaysia, Taiwan, and Europe over the past decade.3e8
The nonmedical use of ketamine has been illegal in Taiwan since
it was classiﬁed as a class 3 drug in 2003. Ketamine is now the most
common illicit drug of abuse detected by the Food and Drug
Administration in Taiwan since 2006.
Clinically, the common presentations are transient and self-
limiting cardiovascular stimulation, acute psychological experi-
ences, abdominal pain, and lower urinary tract symptoms,
including frequency, urgency, suprapubic pain, dysuria, and he-
maturia.3 Ketamine cystitis (KC) shares many common histopath-
ological features with interstitial cystitis/bladder pain syndrome
(IC/BPS), including urothelial ulceration, inﬂammatory celliwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. Intravenous pyelography in a man with ketamine cystitis reveals bilateral
hydronephroureters and contracted urinary bladder.
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the degrees of bladder wall inﬂammation and ﬁbrosis are more
severe in KC, which results in a contracted bladder and upper uri-
nary tract damage and hydronephrosis, vesicoureteral reﬂux, and
recurrent urinary tract infection.5 Several treatment modalities
have been employed; however, most KC patients cannot achieve
symptomatic relief with these treatments. In severe cases, partial
cystectomy and enterocystoplasty are necessary to restore normal
bladder capacity and normal living activities.5 In this article, we
review the available literature regarding the urological impact of
ketamine abuse and its management.
2. Epidemiology
Ketamine is a controlled drug in many countries and is now
under international control; however, the precise prevalence of
recreational, nonmedical ketamine use is unknown. Several indi-
vidual country studies revealed that the background population use
rates of ketamine are around 0.1e4%.10e13 Geographically, recrea-
tional usage of ketamine is seen across the world, but it appears to
be most common in East and Southeast Asia, potentially because of
its relatively low price compared to other psychomimetic
drugs.10e13 In Hong Kong, ketamine was the most commonly
abused drug.5 In the United Kingdom, ketamine has been classiﬁed
as a class C substance since 2006.12 A survey estimates an
increasing number of ketamine abusers from 85,000 in 2006/2007
to 113,000 in September, 2008. The latest data suggests that keta-
mine is now the fourth most popular drug among UK clubbers.
According to the Taiwan Food and Drug Administration's survey,
ketamine is the single most common drug of abuse since 2006. The
age of young people who tested positive for ketamine was less than
a median of 30 years, indicating that the groups abusing ketamine
are getting younger in Taiwan.14 Moreover, the volume of seizures
of street ketamine in Taiwan has increased from 916 kg in 2009 to
1187 kg in 2010.
According to a nationwide questionnaire survey in the United
Kingdom, 26.6% of regular ketamine users reported experiencing at
least one urinary symptom.3 The symptoms were signiﬁcantly
related to both dose and frequency of ketamine use. Another web-
based survey among 18,802 substance users in the United States
revealed that the prevalence of Lower urinary tract symptom (LUTS)
among ever and recent users of ketamine were 28% and 30%,
respectively.15 However, the associations between ketamine and
urological symptoms should be conﬁrmed through longitudinal
studies in the future.Whilst some series have reported a slightmale
predominance, this is insigniﬁcant andnot universallywitnessed. At
the present time itwould seem that KC does not exhibit any sex bias.
3. Pathophysiology
The exact etiopathological mechanism of disease development
of KC remains unknown. Upon histological examination, the uro-
thelium was diffusely denuded. The lamina propria showed
prominent granulation tissue with congested vessels, inﬁltrated
predominantly by lymphocytes and a variable number of eosino-
phils.5 A number of different postulated mechanisms have been
proposed by Chu et al.5 These include: (1) direct effect of ketamine
or its metabolites on bladder interstitial tissues; (2) microvascular
changes in the bladder and possibly kidney by ketamine and/or its
metabolites; (3) indirect effect of ketamine by causing an autoim-
mune reaction against the bladder urothelium and submucosa, due
to circulating ketamine or urinary ketamine and its metabolites;
and (4) bacterial infection.5
According an in vitro toxicity test of ketamine by Shahzad,
(Thesis, University of York, 2011) ketamine is toxic to normalhuman urothelial cells and the toxicity increases as the concen-
tration of ketamine increases. The toxic effects are a direct result of
both itself and its primary metabolite (norketamine) and the effect
is more toxic when used daily than a single dose. Jhang et al16 found
that KC patients had higher serum IgE levels than patients with IC/
BPS or acute bacterial cystitis or controls. Both the serum IgE levels
and the severity of eosinophil inﬁltration were associated with
bladder pain severity in KC patients. In addition, the in vitro toxic
effect was enhanced by the speciﬁc NMDA antagonist MK-801,
despite no direct toxicity. A pilot study performed by immunohis-
tochemistry experiments in KC patients revealed that ketamine
could lead to reactive urothelial changes that could mimic carci-
noma in situ.17 Another pilot study that performed a more detailed
immunohistological study in human KC tissue revealed that uro-
thelial damage by ketamine may induce proliferation in the basal
and intermediate layers to restore the barrier function (Shahzad K.,
Thesis, University of York, 2011).The destruction of the superﬁcial
layer of urothelium leaves the stroma exposed to toxic metabolites
of ketamine, which further induces inﬂammation of the urothelial
tissue and the resultant KC symptoms (Fig. 2).
Another interesting ﬁnding is that ketamine increased the
number of T-cells in the stroma (Shahzad K., Thesis, University of
York, 2011). This might suggest that the toxic effects of ketamine on
the bladder urothelium are twofold: direct toxic effect on the su-
perﬁcial cells and a receptor-mediated effect to damage the deeper
tissue. This might explain why IC/BPS and KC share many clinical
and histopathological features, but the degree of bladder wall
inﬂammation and ﬁbrosis are more severe in KC. This ﬁnding was
also conﬁrmed by another pilot study performed by Lee et al,18
which revealed that decreased expression of E-cadherin and
increased apoptosis were more severe in KC than in IC/BPS and
these ﬁndings were associated with the clinical symptoms of KC
and IC. Urinary epidermal growth factor levels have been found to
Fig. 2. Videourodynamic ﬁndings in ketamine cystitis reveals severe contracted bladder with poor compliance and bilateral vesicoureteral reﬂux.
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In addition, the severe pain induced by KC could be due to a spe-
ciﬁc neurogenic mechanism in which the lamina propria of KC was
replete with ﬁne neuroﬁlament protein nerve ﬁbers and also
prominent peripheral nerve fascicle hyperplasia.19 Enhanced non-
cholinergic contractions and P2X1 receptor expression in the ke-
tamine bladder may underlie detrusor overactivity of KC.20 In
addition, phosphorylation of transgelin has been identiﬁed in long-
term ketamine abusers' bladders.21 In a nutshell, ketamine and its
metabolites not only have a direct impact on the urothelium and
underline subcutaneous tissues, but also have unexplained direct or
indirect impacts on bladder neurological pathways.Fig. 3. The bladder histopathology of ketamine cystitis. The lamina propria shows
prominent granulation tissue with congested vessels, inﬁltrated predominantly by
lymphocytes (magniﬁcation 100).4. Clinical presentation
Shahani et al22 ﬁrst described the urological presentations in
ketamine nonmedical abusers in 2007. After that, several clinical
series detailed the clinical pictures of KC. Clinically recreational
ketamine users presented with a wide range of LUTS, including
urgency, frequency, severe dysuria, urine leakage, and gross he-
maturia. The time of onset of LUTS after ketamine abuse ranged
from a few days to a few years.2 It is still unclear whether the
ingested dosage directly related to the onset time of LUTS. However,
it is clear that KC was rarely associated with the medical use of
ketamine.23 The clinical pictures of KC share many common clinical
features with IC, thus, the IC questionnaire is the preferred one to
record the lower urinary tract symptoms of KC (Fig. 3).
Urine analysis and culture among KC patients always revealed
sterile urine or sterile pyuria. Rarely, contaminated growth or
bacterial pyuria was presented and mainly in female patients.5
According to a population-based questionnaire, ketamine users
with a more frequent intake (> 2 hits/wk) for at least 1 year had a
greater chance of having altered bladder function. In addition, these
early changes of KC could be normalized after at least 1 year of
abstinence.24 The typical cystoscopic ﬁndings were various degrees
of epithelial inﬂammation neovascularization, ulceration, and
petechial hemorrhages in severe cases.5 The classical computed
tomography (CT) ﬁndings included generalized bladder wall
thickening, small bladder capacity, and perivesical inﬂammation.
Nearly half of the KC patients revealed hydronephrosis on diag-
nosis. Among them, one third had a ureteral wall thickening and
less commonly, a ureteropelvic junction involvement.25 In extreme
cases, ureteral lumen narrowing and strictures could be found
under CT and intravenous pyelography (Fig. 1).26 Thus, in severe
cases who initially presented with hydronephrosis, an intravenous
pyelography or a CT scan would beneﬁt KC patients to rule out the
possibilities of ureteral wall thickening, stricture, and ureteropelvic
junction involvement.
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capacity (< 100 mL), a reduced bladder compliance, and sometimes
combined with detrusor overactivity at a very low bladder infusion
volume. Less commonly, vesicoureteral reﬂux could be identiﬁed as
a secondary event due to a severely contracted bladder.5 There
were no signiﬁcant differences in UDS parameters between high
dose and low dose abusers, or the long- and short-term abusers.
The maximum bladder capacity under anesthesia may be a better
predictor of the disease progression of KC when compared with the
UDS.27 Whenever KC patients present with severe frequency, noc-
turia with a voiding diary of small voiding volume and the possi-
bility of severely contracted bladder with poor compliance cannot
be ruled out. A UDS, or even better a Videourodynamic study
(VUDS), will providemore information regarding the compliance of
bladder and also the possibility of further upper tract damage.
5. Management
Several pathophysiological mechanisms have been postulated,
however, the disease development map remains unclear. Hence, no
single deﬁnite treatment has been reported to date. According to
the largest prevalence study in the UK, of the regular ketamine
users who reported urinary tract symptoms, 51% reported
improvement in urinary symptoms upon cessation of use.3 In
addition, for KC patients who failed to discontinue ketamine
addiction, disease progression is always the fate.5,28,29 Thus, early
diagnosis of KC and abstinence are the two most important issues
that should be incorporated in every multidisciplinary approach
before irreversible bladder and renal function damage occur
(Fig. 4).
Several therapeutic agents, mainly symptomatic, have been
employed, including antibiotics, nonsteroid antiinﬂammatory
drugs, steroids, and anticholinergics. However, none of the above
have achieved a signiﬁcant and durable effect.5 IC and KC share
many clinical and pathological features, including epithelial
inﬂammation, neovascularization, ulceration, and impaired uro-
thelium impermeability, which has led to the use of urothelium
protective agents like chondroitin sulfate, pentosan polysulfate, and
hyaluronic acid (Cystistat). One case report illustrates one patient's
successful response to chondroitin sulfate 0.2% (Gepan) over a 1
year period.30 In case series studies, the cessation of ketamine use
and the addition of oral pentosan polysulfate or intravesical hyal-
uronic acid also provided some symptomatic beneﬁt clinically.31,32
In brief, urothelium protective agents may provide some clinicalFig. 4. The ureteral wall was densely inﬁltrated with inﬂammatory cells such as mast
cells and eosinophils.beneﬁt, mainly symptomatic, in the short-term, but further pro-
spective randomized trials with longer follow up are needed.
Recent evidence suggests that botulinum toxin typeA could
signiﬁcantly improve symptoms such as daytime frequency, noc-
turia, pain, quality of life, and bladder capacity in IC/BPS pa-
tients.33,34 In a pilot study, intravesical injection of botulinum toxin
A was shown to be effective in reducing frequency, dysuria, and
increasing bladder capacity after 4 weeks of treatment in KC pa-
tients.35 However, another case report revealed ineffective therapy
of botulinum toxin in a non-cessation ketamine user.36 Thus, it is
still controversial whether botulinum toxin injection provides
clinical beneﬁt to KC patients; further clinical trial investigation is
mandatory.
At the end, in severe cases with a small contracted bladder, poor
bladder compliance and hydronephrosis, urinary diversion may be
the ﬁnal strategy. In a small case series, augmentation cystoplasty
in severely contracted bladders was shown to increase the bladder
capacity (from 37 mL to 400e500 mL) dramatically.37 Although, in
this study, the surgical approach is effective in symptomatic relief,
further deterioration of renal function could be the consequence of
new onset ureteral strictures. Another pilot study in 14 KC patients
revealed the most promising results thus far, with signiﬁcant
improvement in LUTS after augmentation cystoplasty. Surprisingly,
all hydronephrosis resolved after surgery.38 Whether the bladder
should be totally removed at the time of reconstruction is still
controversial.
The goal of treatment for KC related bladder pain is to increase
bladder capacity with good compliance, to decrease the detrusor
pressure to prevent kidney injury, as well as to eradicate the
abnormal painful sensation from the diseased bladder other than
the trigone. Our recent study has demonstrated that augmentation
enterocystoplasty successfully reduces the bladder pain, improves
quality of life, and increases bladder capacity in refractory chronic
KC-related bladder pain. Patients after augmentation enter-
ocystoplasty can resume normal life and return to society for work.
However, patients with ketamine reuse may have symptom relapse
and recurrent urinary tract infection.
In conclusion, KC is an increasing problem among our younger
generations due to its recreational usage and easy availability.
Unfortunately, a clear pathophysiological mechanism is still not
available thus far. In addition, urologists have very limited effective
treatment strategies to control the lower urinary tract problem
caused by ketamine abuse. One deﬁnite thing is that if ketamine
cessation is not addressed in the treatment program, further
development of LUTS and even upper urinary tract deterioration is
always the fate of KC.
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